Investigation of Adiponectin, Leptin, Retinol Binding Protein-4 and Resistin Levels in Non-Diabetic and Non-Obese Patients With Non-Alcoholic Fatty Liver Disease

Ikizek, Mustafa; Kasapoğlu, Benan; Türkay, Cansel

doi:10.17554/j.issn.2224-3992.2020.09.950

Cited by 1 publication

(2 citation statements)

References 59 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, although the indicators of circulating RBP4 levels were converted to the same units, the values varied from one study to the other. For patients with NAFLD, the highest RBP4 level was 94.6 μg/mL [ 36 ], whereas the lowest was only 0.69 μg/mL [ 30 ]. This variation may be related to the differences in the assay methods and experimental kits.…”

Section: Discussionmentioning

confidence: 99%

“…Studies have shown that the diagnostic methods for NAFLD may be a source of heterogeneity, but the application of liver biopsy as a diagnostic method for NAFLD has been less well studied, which inevitably has certain deviations. Fourth, although RBP4 belongs to the lipid family and is closely related to IR, HOMA-IR has not been covered in most articles [ 24 , 36 – 38 ]. Thus, it is impossible to perform reasonable subgroup analysis and meta-regression based on HOMA-IR.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The relationship between NAFLD and retinol-binding protein 4 - an updated systematic review and meta-analysis

Yang

et al. 2023

Lipids Health Dis

View full text Add to dashboard Cite

Purpose Retinol-binding protein 4 (RBP4) has been considered to be related to metabolic related diseases, such as hyperuricemia, obesity, and diabetes mellitus. However, whether nonalcoholic fatty liver disease (NAFLD) is related to RBP4 is unclear. Previous studies on the relationship between NAFLD and RBP4 levels have yielded inconsistent results. Hence, this meta-analysis was aimed to clarify whether circulating RBP4 levels are in relation to the risk of NAFLD. Methods A meta-analysis was performed by applying observational studies to evaluate circulating RBP4 levels and NAFLD. Eligible studies published up to September 23, 2022, were searched in Embase, PubMed, and Cochrane databases. Results In this study, 17 cross-sectional studies involving 8423 participants were included. Results from a random effects model showed that circulating RBP4 levels were higher in NAFLD patients than non-NAFLD (standardized mean difference (SMD) 0.28; 95% confidence intervals (CI): 0.11–0.46, I2: 89.8%). This association was confirmed in the Yellow race. However, no significant association was noted in the Caucasian race. After excluding the morbidly obese Population from the weight loss study (n = 2), the results of the comparison remained largely unchanged (SMD 0.28; 95% CI: 0.10–0.47, I2: 90.8%). Remarkable publication bias was not found. Although considerable heterogeneity was observed among the studies, no potential sources of heterogeneity were found in the subgroup analysis. Diagnostic methods for NAFLD were determined to be a potential source of statistical heterogeneity in meta-regression. Conclusion The findings provide evidence that NAFLD patients exhibit higher levels of circulating RBP4 compared with controls, but high heterogeneity was observed. Thus, a high RBP4 level is probably a potential risk factor for NAFLD. To confirm the causal link between NAFLD and RBP4 level of causality, further prospective cohort studies are needed.

show abstract

Section: Discussionmentioning

confidence: 99%